In silico analysis of potential human T Cell antigens from Mycobacterium tuberculosis for the development of subunit vaccines against tuberculosis

Immunological Investigations

Volumn 43, Issue 2, 2014, Pages 137-159

  Devasundaram, Santhi ^a   Deenadayalan, Anbarasu ^a   Raja, Alamelu ^a  

^a INDIAN COUNCIL OF MEDICAL RESEARCH   (India)

Author keywords

Epitopes; Major histocompatibility complex; Promiscuous peptides; T Cell antigens; Tuberculosis

Indexed keywords

BCG VACCINE; GAMMA INTERFERON; HLA A ANTIGEN; HLA DR ANTIGEN; HLA DR1 ANTIGEN; HLA DR11 ANTIGEN; HLA DR13 ANTIGEN; HLA DR15 ANTIGEN; HLA DR3 ANTIGEN; HLA DR4 ANTIGEN; HLA DR51 ANTIGEN; HLA DR7 ANTIGEN; HLA DR8 ANTIGEN; T LYMPHOCYTE ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ALLELE; AMINO ACID SEQUENCE; ARTICLE; BLOOD SAMPLING; CELLS; CELLULAR IMMUNITY; CLINICAL ARTICLE; COMPUTER MODEL; CYTOKINE RELEASE; HUMAN; LUNG TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS TEST KIT; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; TUBERCULOSIS;

ACYLTRANSFERASES; ADULT; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; CELLS, CULTURED; EPITOPE MAPPING; EPITOPES, T-LYMPHOCYTE; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; INTERFERON-GAMMA; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; PEPTIDE FRAGMENTS; PROTEIN BINDING; T-LYMPHOCYTES; TUBERCULOSIS VACCINES; TUBERCULOSIS, PULMONARY;

EID: 84893418721     PISSN: 08820139     EISSN: 15324311     Source Type: Journal    
DOI: 10.3109/08820139.2013.857353     Document Type: Article

References (47)

1. Andrade Jr DR, Santos SA, Castro I, Andrade DR. (2008). Correlation between serum tumor necrosis factor alpha levels and clinical severity of tuberculosis. Brazil J Infect Dis, 12, 226-33.
2. Brennan MJ, Fruth U, Milstien J, et al. (2007). Development of new tuberculosis vaccines: A global perspective on regulatory issues. PLoS Med, 4, e252.
3. Bui HH, Sidney J, Peters B, et al. (2005). Automated generation and evaluation of specific MHC binding predictive tools: ARB matrix applications. Immunogenetics, 57, 304-14.
4. Coler RN, Dillon DC, Skeiky YA, et al. (2009). Identification of Mycobacterium tuberculosis vaccine candidates using human CD4 T-cells expression cloning. Vaccine, 27, 223-33.
5. Deenadayalan A, Heaslip D, Rajendiran AA, et al. (2010). Immunoproteomic identification of human T cell antigens of Mycobacterium tuberculosis that differentiate healthy contacts from tuberculosis patients. Mol Cell Proteomics, 9, 538-49.
6. Dey B, Jain R, Gupta UD, et al. (2011). A booster vaccine expressing a latency-associated antigen augments BCG induced immunity and confers enhanced protection against tuberculosis. PLoS One, 6, e23360.
7. Dissel JT, Soonawala D, Joosten SA, et al. (2011). Ag85B-ESAT-6 adjuvanted with IC31(R) promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in volunteers with previous BCG vaccination or tuberculosis infection. Vaccine, 29, 2100-9.
8. Flower DR. (2008). Vaccines: Data Driven Prediction of Binders, Epitopes and Immunogenicity in Bioinformatics for Vaccinology. Oxford, UK: Wiley-Blackwell, 167-216.
9. Gomase VS, Chitlange NR. (2010). Immunoproteomics approach for development of MHC binders and fragment based peptide vaccines from Treponema pallidum. J Biosci Technol, 1, 84-9.
10. Grotzke JE, Lewinsohn DM. (2005). Role of CD8 T lymphocytes in control of Mycobacterium tuberculosis infection. Microbes Infect, 7, 776-88.
11. Hanif SN, El-Shammy AM, Al-Attiyah R, Mustafa AS. (2008). Whole blood assays to identify Th1 cell antigens and peptides encoded by Mycobacterium tuberculosis-specific RD1 genes. Medical Prin Pract: Inter J Kuwait Univ Health Sci Centre, 17, 244-9.
12. Harari A, Rozot V, Enders FB, et al. (2011). Dominant TNF-alpha Mycobacterium tuberculosis-specific CD4 T cell responses discriminate between latent infection and active disease. Nature Med, 17, 372-6.
13. Kao FF, Mahmuda S, Pinto R, et al. (2012). The secreted lipoprotein, MPT83, of Mycobacterium tuberculosis is recognized during human tuberculosis and stimulates protective immunity in mice. PLoS One, 7, e34991.
14. Kimman TG, Vandebriel RJ, Hoebee B. (2007). Genetic variation in the response to vaccination. Commun Genet, 10, 201-17.
15. Kumar M, Meenakshi N, Sundaramurthi JC, et al. (2010). Immune response to Mycobacterium tuberculosis specific antigen ESAT-6 among south Indians. Tuberculosis (Edinb), 90, 60-9.
16. Kumar M, Raja A. (2010). Cytotoxicity responses to selected ESAT-6 and CFP-10 peptides in Tuberculosis. Cellular Immunology, 265, 146-55.
17. Kunst H. (2006). Diagnosis of latent tuberculosis infection: The potential role of new technologies. Respir Med, 100, 2098-106.
18. Lahey T, Sheth S, Matee M, et al. (2010). Interferon gamma responses to mycobacterial antigens protect against subsequent HIV-associated tuberculosis. J Infect Dis, 202, 1265-72.
19. Law K, Weiden M, Harkin T, et al. (1996). Increased release of interleukin-1 beta, interleukin-6, and tumor necrosis factor-alpha by bronchoalveolar cells lavaged from involved sites in pulmonary tuberculosis. Amer J Respir Crit Care Med, 153, 799-804.
20. Lu J, Wang C, Zhou Z, et al. (2011). Immunogenicity and protective efficacy against murine tuberculosis of a prime-boost regimen with BCG and a DNA vaccine expressing ESAT-6 and Ag85A fusion protein. Clin Develop Immunol, Epub 2011.
21. McShane H, Pathan AA, Sander CR, et al. (2005). Boosting BCG with MVA85A: The first candidate subunit vaccine for tuberculosis in clinical trials. Tuberculosis, 85, 47-52.
22. Mori T, Sakatani M, Yamagishi F, et al. (2004). Specific detection of tuberculosis infection: An interferon-7-based assay using new antigens. Amer J Respir Crit Care Med, 170, 59-64.
23. Mustafa AS, Shaban FA. (2006). ProPred analysis and experimental evaluation of promiscuous T-cell epitopes of three major secreted antigens of Mycobacterium tuberculosis. Tuberculosis (Edinb), 86, 115-24.
24. Nielsen M, Lundegaard C, Worning P, et al. (2003). Reliable prediction of T-cell epitopes using neural networks with novel sequence representations. Protein Sci, 12, 1007-17.
25. Noguchi H, Kato R, Hanai T, et al. (2002). Hidden Markov model-based prediction of antigenic peptides that interact with MHC class II molecules. J Biosci Bioeng, 94, 264-70.
26. Oftung F, Lundin KEA, Geluk A, et al. (1997). Primary structure and MHC restriction of peptide defined T-cell epitopes from recombinantly expressed mycobacterial protein antigens. Med Princ Pract, 6, 66-73.
27. Olsen AW, Hansen PR, Holm A, Andersen P. (2000). Efficient protection against Mycobacterium tuberculosis by vaccination with a single subdominant epitope from the ESAT-6 antigen. Euro J Immunol, 30, 1724-32.
28. Pal PG, Horwitz MA. (1992). Immunization with extracellular proteins of Mycobacterium tuberculosis induces cell-mediated immune responses and substantial protective immunity in a guinea pig model of pulmonary tuberculosis. Infect Immun, 60, 4781-92.
29. Palma C, Iona E, Giannoni F, et al. (2007). The Ag85B protein of Mycobacterium tuberculosis may turn a protective immune response induced by Ag85B-DNA vaccine into a potent but non-protective Th1 immune response in mice. Cell Microbiol, 9, 1455-65.
30. Raghavan S, Selvaraj P, Swaminathan S, et al. (2009). Haplotype analysis of HLA-A,-B antigens and-DRB1 alleles in south Indian HIV-1-infected patients with and without pulmonary tuberculosis. Int J Immunogenet, 36, 129-33.
31. Sable SB, Verma I, Behera D, et al. (2005). Human immune recognition-based multicomponent subunit vaccines against tuberculosis. Eur Respir J, 25, 902-10.
32. Sampaio LH, Stefani MM, Oliveira RM, et al. (2011). Immunologically reactive M. leprae antigens with relevance to diagnosis and vaccine development. BMC Infect Dis, 11, 26.
33. Schluger NW, Rom WN. (1998). The host immune response to tuberculosis. Am J Respir Crit Care Med, 157, 679-69.
34. Scholvinck E, Wilkinson KA, Whelan AO, et al. (2004). Gamma interferon-based immunodiagnosis of tuberculosis: Comparison between whole-blood and enzyme-linked immunospot methods. J Clin Microbiol, 42, 829-83.
35. Sikora A, Kozioł-Montewka M, Ksiazek A, et al. (2013). Assessment of cytokine release after in vitro stimulation of whole blood with legionella pneumophila in immunocompromised patients. Immunol Invest, 42, 1-17.
36. Singh H, Raghava GP (2001). ProPred: Prediction of HLA-DR binding sites. Bioinformatics, 17, 1236-7.
37. Sundaramurthi JC, Brindha S, Shobitha SR, et al. (2012). In silico identification of potential antigenic proteins and promiscuous CTL epitopes in Mycobacterium tuberculosis. Infect Genet Evol, 12, 1312-8.
38. Takenami I, Loureiro C, Machado Jr A, et al. (2013). Blood cells and interferon-gamma levels correlation in latent tuberculosis infection. ISRN Pulmonol, 2013, 1-8.
39. Talreja J, Bhatnagar A, Jindal SK, et al. (2003). Influence of Mycobacterium tuberculosis on differential activation of helper T-cells. Clin Exp Immunol, 131, 292-8.
40. Torres M, Herrera T, Villareal H, et al. (1998). Cytokine profiles for peripheral blood lymphocytes from patients with active pulmonary tuberculosis and healthy household contacts in response to the 30-kilodalton antigen of Mycobacterium tuberculosis. Infect Immun, 66, 176-80.
41. Vijaya Lakshmi V, Mustafa MI, Santhosh A, et al. (2005). Frequencies of HLA-A,-B,-Dr and-DQ phenotypes in the United Arab Emirates population. Tissue Antigens 66, 107
42. Errata. Tissue Antigens 66 (4), 341-341.
43. Vijaya Lakshmi V, Rakh SS, Anu Radha B, et al. (2006). Role of HLA-B51 and HLA-B52 in susceptibility to pulmonary tuberculosis. Infect Genet Evol, 6, 436-9.
44. Weir RE, Morgan AR, Britton WJ, et al. (1994). Development of whole blood assay to measure T cell responses to leprosy: A new tool for immunoepidemiological field studies of leprosy immunity. J Immunol Meth, 176, 93-101.
45. World Health Organization (2012) WHO Global tuberculosis control 2012. Available from: http://apps.who.int/iris/bitstream/10665/75938/1/9789241564502- eng.pdf.
46. Zhang GL, Khan AM, Srinivasan KN, et al. (2005). MULTIPRED: A computational system for prediction of promiscuous HLA binding peptides. Nucl Acids Res, 33, W172-9.
47. Zvi A, Ariel N, Fulkerson J, et al. (2008). Whole genome identification of Mycobacterium tuberculosis vaccine candidates by comprehensive data mining and bioinformatic analyses. BMC Med Genom, 1, 18.